Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Core Viewpoint - Iovance Biotherapeutics, Inc. will host a conference call and live audio webcast on February 24, 2026, to report its fourth quarter and full year 2025 financial results and corporate updates [1]. Company Overview - Iovance Biotherapeutics, Inc. focuses on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [3]. - The company is pioneering a transformational approach to cancer treatment by utilizing the human immune system to recognize and destroy diverse cancer cells [3]. - Iovance's TIL platform has shown promising clinical data across multiple solid tumors, and its product Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication [3]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve the lives of cancer patients [3].